Introduction {#s1}
============

Narcolepsy type 1 (NT1) is a chronic neurological disease characterized by severe sleepiness, cataplexy and other REM sleep-like episodes intruding into wakefulness (namely hallucinations, sleep paralysis, automatic behaviors), and disrupted nocturnal sleep ([@B1]).

NT1 is caused by loss of hypothalamic hypocretinergic neurons, reflected by low (\< 110 pg/mL) hypocretin-1 (or orexin A) levels in cerebrospinal fluid (CSF hctr-1) ([@B2]).

Disease onset often occurs in childhood and early adolescence and is most frequently accompanied by a rapid weight gain, resulting in overweight or obesity ([@B3]--[@B6]).

Although the mechanisms leading to weight gain in NT1 have yet to be elucidated ([@B7]), its management is of utmost importance as it represents an additional disease burden, negatively impacting on children\'s psychosocial functioning and increasing the cardiovascular and metabolic risk ([@B5], [@B8]).

The promotion of regular physical activity is among the most effective approaches to control weight in overweight children and adolescents ([@B9]). Although never investigated in narcolepsy patients, engagement in physical activity is associated with increased sleep duration and higher sleep quality in healthy subjects and in primary insomnia patients ([@B10], [@B11]).

In this study we analyzed the influence of regular physical activity on sleep/wake profile, sleepiness, metabolic and anthropometric features in a large cohort of drug-naïve NT1 children and adolescents.

Materials and methods {#s2}
=====================

Participants
------------

Fifty drug-naïve NT1 patients ≤ 18 years of age (56% males, age = 12.58 ± 2.94 years, range 6-17) were included. All patients presented with excessive daytime sleepiness, video-documented cataplexy, mean sleep latency ≤ 8 min (3.65 ± 3.20 min) with ≥ 2 sleep onset REM periods (SOREMPs, mean = 4.56 ± 0.70) at multiple sleep latency test (MSLT), and low CSF hctr-1 levels (24.83 ± 31.90 pg/mL). All patients carried the HLA DQB1^\*^06:02 allele. Data collection and database formation were approved by the local health trust\'s ethics committee (Comitato Etico Interaziendale Bologna-Imola, CE-BI, Prot. Num. 17009) and written informed consent was signed by parents of patients.

Sleep and napping behavior assessment
-------------------------------------

Nocturnal sleep and diurnal naps were assessed through seven days of at-home actigraphic monitoring (Micro Motionlogger Watch, Ambulatory Monitoring Inc.). Devices were placed on the non-dominant wrist and initialized to collect and store motor activity in 1-min epochs.

Actigraphy was performed before diagnostic hospitalization, during the regular school-week. The description of the actigraphic variables considered for this work is reported in the [Supplementary Material](#SM2){ref-type="supplementary-material"} ([@B12]).

Participants also filled in a daily sleep diary and indicated nocturnal rest period and diurnal naps through the event-marker button.

Physical activity and cataplexy assessment
------------------------------------------

Participants and their parents underwent a brief interview aimed to collect information on physical activity and cataplexy.

Regular engagement in leisure-time physical activity (LTPA), and whether patients performed their habitual physical activity schedule during the recording week, has been assessed by questions validated in other studies (namely "*Do you usually undertake physical/sporting activities after school?"* and "*During the last seven days, how many times did you perform physical/sporting activities after school that increase your heart rate and make you get out of breath some of the time?"* ([@B13], [@B14]). Information on type of activity, frequency (range 1--7 days), and duration were also collected. Cataplexy frequency and cataplexy occurrence, during or immediately after (within 15 min) performing physical/sporting activities, was also assessed through semi-structured clinical interview ([@B12]). Chronotype was assessed by means of the Italian version of the reduced Morningness-Eveningness questionnaire for Children and Adolescents (*r*MEQ-CA) ([@B15]); subjective sleepiness was assessed with the Epworth Sleepiness scale for children and adolescents (ESS-CHAD) ([@B16]).

Anthropometric and metabolic assessment
---------------------------------------

Height, weight, and body mass index (BMI) were measured for each participant by using a portable stadiometer (Harpenden Portable Stadiometer); BMI percentile was determined in comparison with the Italian growth percentile scales ([@B17]), with underweight defined as BMI \< 5th percentile, normal weight as BMI \>5th and \< 85th percentile, overweight between 85th and 95th percentile, and obesity as BMI\>95th ([@B18]). Blood samples were collected after fasting from midnight and analyzed for blood glucose, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides.

Statistical analyses
--------------------

For statistical purposes, NT1 children and adolescents were classified either as "LTPA*s*" (*n* = 30) if they were engaged in any type of LTPA for at least 60 min twice a week or "No-LTPA*s*" (*n* = 20). Individual information on physical activity schedule is reported as Supplementary Material (Table [S1](#SM1){ref-type="supplementary-material"}).

Group differences in demographic, clinical, anthropometric/metabolic data and actigraphic parameters were analyzed by means of chi-squared and independent sample *t*-test, followed by effect size computation (Cohen\'s *d*). Analyses were conducted with IBM SPSS Statistics 19 software (SPSS, Inc. Chicago, Ill); *p*-value \< 0.05 was considered statistically significant.

Results {#s3}
=======

Demographics, clinical, anthropometric, and metabolic data are reported in Table [1](#T1){ref-type="table"}. Significant differences were observed in subjective sleepiness, with LTPA*s* presenting lower ESS-CHAD score than No-LTPA*s*, but not in objective sleep propensity or SOREMPs number at the MSLT. No differences were observed in cataplexy frequency. Significant differences were also observed in anthropometric/metabolic features, with LTPA*s* presenting lower BMI, a different BMI category distribution, and higher HDL cholesterol level than No-LTPA*s*.

###### 

Demographic, clinical, anthropometric and metabolic data of NT1 children and adolescents relative to their engagement in leisure-time physical/sporting activities.

                                                                                          **NT1-LTPA*s* (*n* = 30)**    **NT1-No LTPA*s* (*n* = 20)**           ***t*~(48)~**                            ***p***
  ------------------------------------------------- ------------------------------------- ----------------------------- --------------------------------------- ---------------------------------------- ---------
                                                                                          **Mean** ± **SD**             **Mean** ± **SD**                                                                
  **DEMOGRAPHIC AND CLINICAL DATA**                                                                                                                                                                      
  Male/female                                       17/13                                 11/9                          0.01[^†^](#TN1){ref-type="table-fn"}    *ns*                                     
  Age at NT1 onset, y                               9.21 ± 2.93                           8.94 ± 3.83                   0.28                                    *ns*                                     
  Age at observation, y                             12.16 ± 2.70                          13.23 ± 3.23                  −1.27                                   *ns*                                     
  Diagnostic delay, y                               2.74 ± 2.77                           4.01 ± 2.89                   −1.56                                   *ns*                                     
  ESS-CHAD                                          13.40 ± 3.02                          16.10 ± 3.40                  −2.94                                   0.005                                    
  Cataplexy frequency, (%)                          ≥1/day                                60                            65                                      291.5[^††^](#TN2){ref-type="table-fn"}   *ns*
                                                    \< 1/day and ≥1/week                  23.3                          15                                                                               
                                                    \< 1/week and ≥1/month                3.3                           5                                                                                
                                                    \< 1/month and ≥1/in 3 months         10.0                          10                                                                               
                                                    \< 1/in 3 months and ≥1/in 6 months   3.3                           5                                                                                
  Chronotype (m\\i\\e)                              8\\20\\2                              1\\15\\4                      5.03[^†^](#TN1){ref-type="table-fn"}    *ns*                                     
  **NEUROPHYSIOLOGICAL AND BIOCHEMICAL DATA**                                                                                                                                                            
  MSLT-sol, min                                     3.95 ± 3.50                           3.21 ± 2.71                   0.80                                    *ns*                                     
  SOREMP, n°                                        4.57 ± 0.63                           4.55 ± 0.83                   286[^††^](#TN2){ref-type="table-fn"}    *ns*                                     
  CSF hcrt-1, pg/mL                                 27.71 ± 27.20 (*n* = 26/30)           21.09 ± 37.57 (*n* = 20/20)   0.69                                    *ns*                                     
  HLA DQB1^\*^0602 positivity                       30/30                                 20/20                                                                                                          
  **ANTHROPOMETRIC AND METABOLIC FEATURES**                                                                                                                                                              
  BMI                                               22.87 ± 3.88                          27.94 ± 8.41                  −2.88                                   0.006                                    
  BMI category (underweight\\normal\\over\\obese)   0/16/9/5                              1/1/12/6                      13.29[^†^](#TN1){ref-type="table-fn"}   \< 0.005                                 
  Glucose, mg/dL                                    82.93 ± 7.07                          80.67 ± 6.36                  1.12                                    *ns*                                     
  Total cholesterol, mg/dL                          172.40 ± 29.90                        168.40 ± 40.80                0.40                                    *ns*                                     
  HDL-C, mg/dL                                      56.03 ± 13.15                         48.35 ± 11.03                 2.16                                    \< 0.05                                  
  LDL-C, mg/dL                                      101.30 ± 26.40                        101.40 ± 29.67                −0.01                                   *ns*                                     
  Triglycerides, mg/dL                              88.60 ± 44.41                         93.45 ± 43.31                 −0.38                                   *ns*                                     

NT1-LTPAs, Narcolepsy type 1 subjects regularly engaged in leisure-time physical/sporting activities; NT1-No LTPAs, Narcolepsy type 1 subjects not engaged in leisure-time physical/sporting activities; ESS-CHAD, Epworth sleepiness scale for children and adolescent; Chronotype (m, morning type; i, intermediate type; e, evening type); MSLT-sol, mean sleep latency at MSLT; SOREMPs, sleep-onset REM periods at MSLT; CSF hcrt-1, cerebrospinal fluid hypocretin-1; BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Unless otherwise specified, the t-test was used for group comparisons.

*Chi-squared test*,

*Mann-Whitney U test*.

Actigraphic variables are reported in Table [2](#T2){ref-type="table"}. Significant differences were observed in nocturnal sleep duration and quality, with LTPA*s* displaying increased *e*TST and sleep efficiency, reduced *e*WASO and SMA, despite increased frequency of nocturnal awakenings when compared to No-LTPA*s*. Concerning the daytime period, a significant increase of DMA, reduced *e*DTST and naps frequency were observed in LTPA*s*.

###### 

Actigraphic nighttime and daytime parameters of NT1 children and adolescents with respect to engagement in leisure-time physical/sporting activities.

                                **NT1-LTPA*s* (*n* = 30) Mean ± SD**   **NT1-No LTPA*s* (*n* = 20) Mean ± SD**   ***t*~(48)~**   ***p***     **ES**
  ----------------------------- -------------------------------------- ----------------------------------------- --------------- ----------- --------
  **SLEEP TIMING**                                                                                                                           
  Bedtime                       22:56 ± 00:56                          23:33 ± 01:24                             −1.83           *ns*        
  Wake time                     07:21 ± 00:46                          07:50 ± 01:27                             −1.53           *ns*        
  Midpoint                      03:09 ± 00:42                          03:42 ± 01:16                             −1.95           *ns*        
  TIB, min                      504.44 ± 59.20                         494.98 ± 79.88                            0.53            *ns*        
  **NIGHTTIME PERIOD**                                                                                                                       
  *e*TST, min                   355.25 ± 57.56                         304.41 ± 67.49                            2.86            \< 0.01     0.75
  *e*Sleep efficiency, %        70.64 ± 7.92                           62.21 ± 13.02                             2.85            \< 0.01     0.65
  *e*WASO, min                  135.25 ± 42.94                         168.43 ± 70.64                            −2.07           \< 0.05     −0.47
  *e*Awakenings, n°             33.43 ± 7.37                           28.50 ± 8.06                              2.23            \< 0.05     0.61
  *e*Prolonged awakenings, n°   8.77 ± 3.46                            9.74 ± 3.08                               −1.02           *ns*        
  SMA, counts                   24.25 ± 5.72                           36.08 ± 15.22                             −3.88           \< 0.0005   −0.78
  *e*Longest sleep, min         68.34 ± 13.19                          63.74 ± 16.39                             1.10            *ns*        
  **DAYTIME PERIOD**                                                                                                                         
  DMA, counts                   208.42 ± 22.15                         190.29 ± 25.24                            2.68            0.01        0.72
  *e*DTST, min                  59.34 ± 30.07                          84.75 ± 29.67                             −2.94           0.005       −0.86
  *e*Nap, n°                    6.30 ± 2.15                            10.30 ± 3.31                              −5.19           \< 0.0001   −1.21
  *e*NapD, min                  54.89 ± 17.98                          54.95 ± 26.75                             −0.01           *ns*        
  *e*24hTST, min                414.59 ± 65.04                         389.16 ± 73.74                            1.28            *ns*        

*NT1-LTPAs, Narcolepsy type 1 subjects regularly engaged in leisure-time physical/sporting activities; NT1-No LTPAs, Narcolepsy type 1 subjects not engaged in leisure-time physical/sporting activities; ES, Cohen\'s d; TIB, time in bed; eTST, estimated total sleep time; eWASO, estimated wake after sleep onset; SMA, mean activity counts during TIB; DMA, mean activity counts during daytime; eDTST, estimated total sleep time during daytime; eNap, total number of daytime estimated sleep episodes during the recording period; eNapD, mean duration of longest estimated sleep episode; e24hTST, sum of all epoch scored as sleep across nocturnal and diurnal period*.

Discussion {#s4}
==========

This is the first study that investigated anthropometric/metabolic features and sleep/wake profile with respect to engagement in physical/sporting activity among pediatric NT1 patients.

Overall, our results highlight a beneficial association between regular LTPA and several disease-related aspects. Although we confirmed the over-representation of overweight and obesity among pediatric NT1 patients (42% of subjects being overweight and 22% being obese) ([@B4], [@B5]), our results showed that NT1 subjects regularly engaged in LTPA (60% of this cohort) presented with overall lower BMI and lower prevalence of overweight and obesity (30% overweight, 17% obese) compared to No-LTPA*s* (60% overweight, 30% obese).

Moreover, regular involvement in LTPA turned out to be associated with favorable differences in lipid-lipoprotein profile as LTPA*s* present with higher levels of HDL-C and lower levels of triglycerides when compared to No-LTPA*s*, although the latter difference did not reach statistical significance. Although these results are in line with previous studies on healthy children and adolescents reporting higher HDL-C and lower triglycerides levels in physically active subjects, further confirmation is required by means of interventional studies in NT1 patients ([@B19]).

Actigraphy objectively documented higher sleep quality (higher estimated sleep efficiency and lower *e*WASO and SMA) and increased sleep duration (higher *e*TST) in LTPA*s* compared to No-LTPA*s*, without significant differences in TIB and in the timing of nocturnal rest period, highlighting the positive association between regular physical activity and nocturnal sleep quality.

The abovementioned results are in line with results of previous studies in good sleepers and primary insomnia patients and, for the first time, these findings extend to patients suffering from NT1 ([@B11], [@B20]).

Moreover, regular engagement in LTPA was also associated with a different diurnal behavior, as LTPA*s* took fewer naps, spending less time asleep during daytime. Differences in subjective sleepiness levels properly confirmed the actigraphic diurnal profile, with LTPA*s* displaying lower ESS-CHAD score than No-LTPA*s*. Engagement in LTPA was not associated with differences in cataplexy frequency. However, it is of high interest to highlight that none of the children and adolescents reported to experience cataplectic attacks during or immediately after having performed physical activity. This finding could have important clinical implications, since concerns have been raised about the potential adverse effect of physical activity on cataplexy frequency ([@B21]). Indeed, in a murine model of NT1, physical exercise (wheel running) increased the total amount of wakefulness to the detriment of a negative effect on cataplexy and authors pointed out the need to optimize cataplexy control to derive benefit from physical activity ([@B21], [@B22]).

Our study suffers from the inherent limitations of a cross-sectional design, in particular it precludes the possibility of ruling out reverse causation (i.e., children are able to perform physical/sports activities because they are not overweight or obese) and calls for further interventional studies, in pharmacologically untreated and treated patients. Moreover, food intake was not monitored in the present study.

Nonetheless, our study showed that regular engagement in leisure-time physical/sports activity is associated with significant differences in children\'s anthropometric features, sleepiness and sleep/wake profile and does not seem to trigger cataplexy, thus providing a first rationale to implement regular physical activity as a complementary non-pharmacological approach to assist the management of pediatric NT1 cases.
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